Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of September 22.
MD Magazine staff spent last week jet-setting — from the Psych Congress 2017 in the Big Easy, to the Heart Failure Society of America's 21st Annual Scientific Meeting in Houston, to the PER 2017 Cardio-Endo-Renal Collaborative in the Big Apple.
But news doesn't stop for conferences. In fact, that's when it seems to pick up even more. Here were the headlines you may have missed while doing your own traveling, with the Connected Clinician's Top Stories of the Week:
Analysis of omalizumab trials has identified asthma patients who are most likely to respond to treatment.
Buprenorphine and methadone — while linked to increased risk of serious side effects — are more beneficial than harmful when combined with benzodiazepines or other central nervous system depressants for opioid addiction care.
The study showed 12.7% of the total infected patients had a recurrent infection.
“We ought to learn as much as we can about what makes these persons unique so we can find more therapeutic options that can be expanded to a larger population.”
Researchers found two loci, TRPM1 and ABHD2/RLBP1, with previously unrecognized associations related to the risk of age-related macular degeneration.
“We are constantly looking for new molecules with which to treat COPD patients.”
Truvada showed efficacy and safety in HIV-susceptible teenage boys — so as long as they kept up with treatment.
The combination is the first once-daily therapy approved in the US that combines 3 active molecules in a single inhaler.
Trispecific antibodies show exceptionally promising results against HIV.